

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)



(10) International Publication Number
WO 2025/021835 A9

(51) International Patent Classification:

A61K 9/127 (2006.01) A61K 47/26 (2006.01)
A61K 31/7105 (2006.01) A61K 47/28 (2006.01)
A61K 31/713 (2006.01) C12N 15/113 (2010.01)
A61K 38/46 (2006.01) C12N 15/11 (2006.01)
A61K 47/14 (2017.01) C12N 15/88 (2006.01)
A61K 47/18 (2017.01) C12N 15/90 (2006.01)
A61K 47/24 (2006.01)

(21) International Application Number:

PCT/EP2024/070941

(22) International Filing Date:

23 July 2024 (23.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2023/070385

23 July 2023 (23.07.2023)

EP

(71) Applicant: MAX-PLANCK-GESELLSCHAFT ZUR
FÖRDERUNG DER WISSENSCHAFTEN E.V.
[DE/DE]; Hofgartenstraße 8, 80539 München (DE).

(72) Inventors: ZERIAL, Marino; c/o Max-Planck-Institut für
molekulare Zellbiologie und Genetik, Pfotenhauerstraße
108, 01307 Dresden (DE). NADLER, Christina; c/o Max-
Planck-Institut für molekulare Zellbiologie und Genetik,
Pfotenhauerstraße 108, 01307 Dresden (DE).


(74) Agent: HÖPFNER, Sebastian; Zwicker Schnappauf &
Partner Patentanwälte PartG mbB, Hansastr. 32, 80686
München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE

Figure 1



(57) Abstract: A composition comprising (a) a therapeutic
agent or a pharmaceutically acceptable salt thereof; (b) a PEG-
monoorthoester-lipid; (c) an amphiphilic lipid; (d) a cationic lipid
and/or a beta-alanyl-prolyl-cysteine methyl ester; and optionally
(e) a steroid and/or a ceramide and/or DOPE. The composition
for use as a medicament.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:

06 November 2025 (06.11.2025)

(15) Information about Correction:

see Notice of 06 November 2025 (06.11.2025)